Not yet recruitingInterventionalPhase 1Last updated Aug 13, 2026

An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease

An Open Label Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of VY1706 in Participants With Early Alzheimer's Disease

Overview

ClinicalTrials.gov ID: NCT07764146
Lead Sponsor: Voyager TherapeuticsINDUSTRY
Brief Summary: VY1706 first in human study in early Alzheimer's Disease is a multicenter dose escalation study
Study Type: Interventional

Status

Overall Status: Not yet recruiting
Start Date: Aug 24, 2026Estimated
Primary Completion Date: Apr 28, 2029Estimated
Completion Date: Apr 28, 2029Estimated

Study Record Dates

First Submitted: Aug 4, 2026
First Submitted that Met QC Criteria: Aug 11, 2026
First Posted: Aug 13, 2026Actual
Last Update Submitted that Met QC Criteria: Aug 11, 2026
Last Update Posted: Aug 13, 2026Actual
Last Verified: Aug 2026

NCT06874621Active, not recruiting

VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease

NCT05291234Completed

A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease

NCT06343636Completed

A Phase 1 Study of VG-3927 in Healthy Adults and Patients With Alzheimer's Disease

NCT07094516Recruiting

A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

NCT07599670Recruiting

A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease

NCT05016427Unknown status

A Study of Possibility of Using Regulatory T Cells(VT301) for Treatment of Alzheimer's Disease